Tejas Savant
Stock Analyst at Morgan Stanley
(3.10)
# 2,463
Out of 5,127 analysts
250
Total ratings
47.52%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $40 → $48 | $43.56 | +10.19% | 15 | Dec 2, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $606.50 | +10.47% | 16 | Dec 2, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $80 → $85 | $68.36 | +24.34% | 6 | Dec 2, 2025 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $24 | $21.92 | +9.49% | 3 | Dec 2, 2025 | |
| PSNL Personalis | Maintains: Equal-Weight | $9 → $11 | $8.38 | +31.34% | 14 | Dec 2, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $265 | $239.56 | +10.62% | 15 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $243.19 | +8.97% | 12 | Dec 2, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $85 → $110 | $98.04 | +12.20% | 3 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $19.29 | +3.68% | 16 | Dec 2, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $69 → $76 | $74.88 | +1.50% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $16 | $15.96 | +0.25% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $145.83 | -28.00% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $12.06 | -0.50% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $12.83 | -37.65% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $5.43 | +28.91% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $10.50 | -33.33% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.85 | +29.87% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $6.56 | +220.12% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $2.04 | -1.96% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $9.06 | +341.50% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.22 | +170.27% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.96 | +101.61% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.25 | -15.25% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.87 | +434.76% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $108.74 | -32.87% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $215.51 | +16.00% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $5.58 | +1,692.11% | 5 | May 12, 2022 |
Veracyte
Dec 2, 2025
Maintains: Underweight
Price Target: $40 → $48
Current: $43.56
Upside: +10.19%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $606.50
Upside: +10.47%
Tempus AI
Dec 2, 2025
Maintains: Overweight
Price Target: $80 → $85
Current: $68.36
Upside: +24.34%
Stevanato Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $24
Current: $21.92
Upside: +9.49%
Personalis
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $8.38
Upside: +31.34%
Natera
Dec 2, 2025
Maintains: Overweight
Price Target: $220 → $265
Current: $239.56
Upside: +10.62%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $243.19
Upside: +8.97%
GRAIL
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $85 → $110
Current: $98.04
Upside: +12.20%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $19.29
Upside: +3.68%
Hologic
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $69 → $76
Current: $74.88
Upside: +1.50%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $15.96
Upside: +0.25%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $145.83
Upside: -28.00%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $12.06
Upside: -0.50%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $12.83
Upside: -37.65%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $5.43
Upside: +28.91%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $10.50
Upside: -33.33%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.85
Upside: +29.87%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $6.56
Upside: +220.12%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $2.04
Upside: -1.96%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $9.06
Upside: +341.50%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.22
Upside: +170.27%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.96
Upside: +101.61%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.25
Upside: -15.25%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.87
Upside: +434.76%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $108.74
Upside: -32.87%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $215.51
Upside: +16.00%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $5.58
Upside: +1,692.11%